Recombinant fragment (around aa 200-500) of human BRCA2 protein (exact sequence is proprietary)
Alternative Names:
BRCA1/BRCA2 containing complex subunit 2, BRCA2, DNA repair associated, BRCC2, Breast and ovarian cancer susceptibility gene early onset, breast and ovarian cancer susceptibility protein 2, Breast cancer 2 early onset, Breast Cancer 2 tumor suppressor, BROVCA2, FACD, FAD1, FANCB, FANCD, FANCD1, Fanconi anemia complementation group D1, GLM3, mutant BRCA2, PNCA2, XRCC11
In 1990, a breast cancer susceptibility gene designated BRCA1 was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2 (breast cancer 2, early onset), located on chromosome 13q13.1, also confers a high incidence of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer. Both BRCA1 and BRCA2 play a role in the maintainance of genome stability, particularly in the homologous recombination pathway for double-strand DNA repair. BRCA2 is regarded as a tumor suppressor gene, tumors with BRCA2 mutations exhibit loss of heterozygosity (LOH) of the wildtype allele. The protein encoded by the BRCA2 gene contains multiple copies of a 70 amino acid motif called the BRC motif. These motifs effect binding to the Rad51 recombinase, which operates in DNA repair.
200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
SDS-PAGE Analysis of Purified BRCA2 Mouse Monoclonal Antibody (BRCA2/2158). Confirmation of Integrity and Purity of Antibody.
